Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
- None.
- None.
The announcement of Know Labs' KnowU, a wearable non-invasive continuous glucose monitor (CGM), signifies a substantial advancement in diabetes management technology. The significance lies in the device's non-invasiveness and the potential to disrupt the current market for glucose monitoring, which primarily relies on invasive blood sampling. The KnowU's use of dielectric spectroscopy and machine learning algorithms to measure glucose levels represents a novel approach, leveraging the dielectric properties of glucose to provide real-time continuous readings. This technology could not only enhance patient comfort and compliance but also reduce the overall cost and waste associated with disposable testing supplies.
Furthermore, the device's potential longevity and rechargeable battery feature suggest a sustainable and cost-effective solution for users. The implications for stakeholders range from improved patient outcomes due to better diabetes management to potential market share gains for Know Labs in the medical device sector. However, the success of the KnowU hinges on its ability to pass FDA clinical trials and demonstrate accuracy and reliability comparable to or exceeding current invasive methods. The long-term impact on the company's financials will depend on the market's acceptance of the technology and its scalability in production.
Know Labs' positioning as a leading IP holder in non-invasive blood glucose monitoring, with an extensive patent portfolio, suggests a competitive edge in the healthcare technology market. The KnowU's market entry could potentially capture a significant share of the diabetes care market, which is expanding due to the increasing prevalence of the disease globally. The ability to collect accelerated data during FDA clinical trials and refine the device accordingly could expedite the commercialization process.
Investors should monitor the progress of these trials closely, as favorable outcomes could lead to substantial stock valuation increases for Know Labs. Conversely, any setbacks or delays in FDA approval could negatively impact investor sentiment. Market adoption will also depend on the integration of the KnowU with healthcare systems and insurance coverage, which could influence its accessibility and affordability. The device's ease of use and connectivity with a companion mobile app are additional factors that could drive consumer adoption and retention.
The announcement of Know Labs' KnowU device and its impending FDA submission is a critical milestone that could have a significant financial impact on the company. The successful development and commercialization of the KnowU could lead to new revenue streams and potentially increase the company's market capitalization. The device's design to eliminate costly disposables and its rechargeable battery could appeal to cost-conscious consumers and insurers, potentially leading to higher adoption rates.
However, investors should consider the capital requirements and risks associated with the clinical trial phase and subsequent marketing and distribution efforts. The financial implications for Know Labs will also depend on the pricing strategy and the ability to scale production to meet potential demand. It is essential to assess the company's financial health and its capacity to navigate the regulatory landscape, including any challenges that may arise during the FDA approval process.
The KnowU incorporates the sensor intended for FDA submission
(Photo: Business Wire)
The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested and proven stable and accurate in the lab setting. It was included in the Company’s prototype to validate stability outside of the lab, and is now miniaturized and wearable.
The KnowU can be worn with an adhesive, allowing the user to clip the sensor on and off, or on the wrist or forearm with a strap. The device, which is significantly smaller and lighter than the prototype, includes on-board computing power and built-in machine learning capabilities. The KnowU is designed to optimize the customer experience – expected to last for years, eliminate costly disposables, have a rechargeable battery, and connect with an easy-to-use companion mobile app. Click here to watch a video for more insight into specific KnowU features.
The KnowU brings Know Labs closer to delivering the world’s first non-invasive blood glucose monitor to the global marketplace. As the Company prepares for FDA clinical trials, the KnowU device will support accelerated data collection, including determining the technology’s performance throughout continuous wear, on different locations on the body, and within more expansive glycemic ranges and diverse populations.
“The prevalence of diabetes is growing globally at an alarming rate. Millions of people face significant barriers in accessing the technology and treatment they need to effectively manage their diabetes,” said Ron Erickson, CEO and Chairman at Know Labs. “Know Labs is committed to delivering an accessible, affordable, and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes. The KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”
The KnowU is built upon the solid scientific foundation underlying Know Labs’ technology. Its proprietary radiofrequency (RF) sensor measures glucose levels using dielectric spectroscopy by rapidly scanning a large range of RF frequencies. It records voltage values detected at each frequency to quantify, with trade-secret machine learning algorithms, real-time continuous blood glucose levels. The KnowU exploits the dielectric properties of glucose, a polar molecule in the body, including its ability to store electrical energy in an electrical field (known as permittivity) as measured through a voltage reading received after broadcasting each frequency. As the leading worldwide IP holder in non-invasive blood glucose monitoring with more than 270 patents issued, pending and in process, Know Labs has created a defensible moat surrounding its technology. For more information, visit https://www.knowlabs.co/technology.
During 2024, Know Labs will deploy the KnowU in large-scale, external clinical trials while making refinements to the device and its algorithms. To learn more about the development process for the KnowU, visit https://www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227401198/en/
For Know Labs Media Inquiries Contact:
Matter Health
Abby Mayo
Knowlabs@matternow.com
Ph. (617) 272-0592
Know Labs, Inc. Contact:
Jordyn Hujar
jordyn@knowlabs.co
Ph. (206) 629-6414
Source: Know Labs, Inc.
FAQ
What is the name of the company mentioned in the press release about the wearable non-invasive continuous glucose monitor?
What is the ticker symbol for Know Labs, Inc.?
What is the name of the wearable non-invasive continuous glucose monitor announced by Know Labs, Inc.?
What technology does the KnowU incorporate for FDA submission?
What capabilities does the KnowU device include?
What is the goal of Know Labs with the KnowU device?
